Armata Pharmaceuticals Inc
$ 7.58
1.47%
12 Jun - close price
- Market Cap 278,268,000 USD
- Current Price $ 7.58
- High / Low $ 7.99 / 7.06
- Stock P/E N/A
- Book Value -8.50
- EPS -7.78
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -34.39 %
- 52 Week High 14.98
- 52 Week Low 1.74
About
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
Analyst Target Price
$17.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-25 | 2025-11-12 | 2025-08-12 | 2025-05-14 | 2025-03-20 | 2024-11-13 | 2024-08-13 | 2024-05-07 | 2024-03-21 | 2023-11-14 | 2023-08-14 |
| Reported EPS | -3.16 | -0.5112 | -0.74 | -0.45 | -0.1973 | -0.2317 | -0.15 | 0.25 | -0.69 | -0.55 | -0.75 | -0.1 |
| Estimated EPS | -0.38 | -0.19 | -0.5 | -0.39 | -0.38 | -0.35 | -0.28 | -0.44 | -0.31 | -0.35 | -0.31 | -0.37 |
| Surprise | -2.78 | -0.3212 | -0.24 | -0.06 | 0.1827 | 0.1183 | 0.13 | 0.69 | -0.38 | -0.2 | -0.44 | 0.27 |
| Surprise Percentage | -731.5789% | -169.0526% | -48% | -15.3846% | 48.0789% | 33.8% | 46.4286% | 156.8182% | -122.5806% | -57.1429% | -141.9355% | 72.973% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARMP
2026-06-01 04:40:46
This article reports that the price target for Armata Pharmaceuticals (ARMP) has been increased by 16.67%, raising it to $17.85. The information, although brief, indicates a positive adjustment in analyst outlook for the company's stock.
2026-05-22 04:08:52
This article provides a stock chart for ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP), displaying its current stock price and trading information as of May 22, 2026. The article offers various security sections including technical analysis, fundamental analysis, forecast, earnings, financials, ownership, and news. It also allows users to view daily, weekly, and monthly charts in different formats.
2026-05-14 01:09:31
Armata Pharmaceuticals (ARMP) reported its Q1 2026 results, showing an EPS of -3.16, significantly missing the estimated -0.38, and a net loss of $115.3 million. Despite the wider loss, the company secured a $25 million credit agreement and received FDA Fast Track and QIDP designations for its lead bacteriophage candidate, AP-SA02, highlighting progress in its clinical development. The company's GF Score is 32/100, indicating heightened risk and a weak financial profile.
2026-05-14 00:39:19
Armata Pharmaceuticals reported its Q1 2026 results, showing increased net loss to $115.3 million but also significant progress in its clinical development with AP-SA02 receiving FDA Fast Track and QIDP designations. The company secured a new $25 million loan from Innoviva to fund the advancement of AP-SA02 into a Phase 3 study, despite a decline in cash reserves to $4.8 million. The market reacted negatively to the financial results, with the stock declining 7.03% on the news.
2026-05-14 00:09:31
Armata Pharmaceuticals (ARMP) reported a first-quarter loss per share of $3.16. This brief article provides only the financial result without further details.
2026-05-13 21:40:23
Innoviva now beneficially owns 82.7% of Armata Pharmaceuticals (ARMP) after a new secured term loan of $25 million was issued. This stake includes existing shares, warrants, and shares from a prior convertible loan. The new loan bears a 14.00% annual interest rate and matures in 2029, is secured, and is not convertible into equity, reinforcing Armata's financial dependence on Innoviva.
